Vis børsmeldingen
Developmental Therapeutics-Immunotherapy to be presented 29 May at the ASCO 2020
virtual meeting
Oslo, Norway, 14 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing oncolytic viruses to target hard-to-treat solid
tumors, today announces that an abstract relating to the dose escalation part of
the ONCOS-102 and durvalumab trial in primary ovarian and colorectal cancer that
has spread to the peritoneum has been selected for presentation at a Poster
Discussion Session during ASCO 2020.
The study is an open label, exploratory phase I/II trial assessing the intra
-peritoneally delivered ONCOS-102 in combination with systemically administered
checkpoint inhibitor durvalumab in patients with platinum-resistant ovarian or
colorectal cancers that have metastasized to the peritoneal cavity. The trial is
designed with a dose-escalation phase assessing three different dosing levels,
followed by an expansion phase with a total of up to 78 patients enrolled into
separate groups of ovarian and colorectal cancer.
In the ASCO abstract, safety, immune activation and clinical response data for
the three dose escalation cohorts will be presented. A total of 17 patients were
enrolled, 4 in cohort A (low dose), 5 in cohort B (middle dose) and 8 in cohort
C (high dose). No dose-limiting toxicities were observed, and the combination
had an acceptable safety profile. Therefore, the high-dose level was selected
for the expansion phase of the trial, which is currently enrolling patients.
Preliminary analyses indicate that the treatment is triggering immune activation
and has clinical activity, which were more pronounced in cohort B and C.
Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said: “We are very
proud that ONCOS-102 was chosen as the oncolytic virus of choice for this trial
and we are equally pleased that the scientific committee has selected our ONCOS
-102 and durvalumab combination abstract for a poster discussion at the upcoming
ASCO meeting. Although it is too early in the trial to interpret the clinical
data, we are happy to have moved into the expansion phase following successful
completion of the dose escalation phase. This is an important clinical trial as
it addresses a disease with a very high unmet medical need while potentially
opening up intra-peritoneal administration as an alternative delivery route for
ONCOS-102.”
Poster discussion Developmental Therapeutics-ImmunotherapyPhase I/II study
sessionAbstract to evaluate systemic durvalumab + intraperitoneal (IP)
title: ONCOS-102 in patients with peritoneal disease who have
epithelial ovarian (OC) or metastatic colorectal cancer
(CRC): Interim phase I clinical and translational
results.
Date / time: 29 May 2020, 8-11AM CDT
Abstract / Poster: 3017 / 81
The abstract can be found here
https://meetinglibrary.asco.org/record/185276/abstract.
The trial is a collaboration between Targovax, AstraZeneca, Cancer Research
Institute (CRI) and Ludwig Cancer Research.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.
Kilde
